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PURPOSE: To characterize the population of HIV+ Brazilian patients with late introduction of antiretroviral therapy (ARVT),
using information from the Laboratory Exam Control System.
METHODS: The study analyzed 84,694 patients, representing all individuals in Brazil age 15 or over with an initial CD4+ T
lymphocyte count requested between 2003 and 2006, and whose ARVT start date was later than their initial CD4+ T cell count.
These patients were considered antiretroviral treatment naive. The initial CD4+ T cell distribution was analyzed according to sex,
age, region and year.
RESULTS: Most of the patients were between 15 and 49 years of age (91%); 56% were males; 76% were asymptomatic; 50%
lived in the Southeastern region of the country, with an additional 20% in the South. Initial CD4+ counts for one-third of the
patients were less than 200 cells/mm3. When combined with the number of symptomatic individuals, 41% of the total group was
in need of immediate ARVT. This group included 47% of the men and 53% of the patients aged 50 years and over.
CONCLUSIONS: Despite universal access to ARVT in Brazil, results show that a high proportion of patients initiate ARVT at an
advanced stage of disease, indicating the need to develop strategies to promote early diagnosis of HIV infection nationwide.
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INTRODUCTION
The quality of life of people living with HIV/AIDS has
improved drastically with the introduction of highly active
antiretroviral therapy (HAART), resulting in a significant
reduction of viral load and an increase of the CD4+ T
lymphocyte count among treatment-naive patients1.
However, access to HAART is uneven, and varies de-
pending on public policies and treatment costs in each
country. In Latin America, according to information from
national AIDS programs, ARVT coverage varies from 15%
in Peru to 100% in Argentina, Brazil and other countries2.
In Brazil, the Ministry of Health began distributing
drugs for prophylaxis and treatment of opportunistic infec-
tions in the mid-1980s. AZT (zidovudine) was the first drug
available in Brazil, beginning in 1991. The combined ef-
fort of patients, civil society groups, and government agen-
cies resulted in the passage of a federal law in 1996 guar-
anteeing the right of all individuals with HIV/AIDS to re-
ceive the drugs necessary for their treatment free of charge3.
The high cost of antiretroviral therapies and the grow-
ing number of patients in need of them have been a con-
tinuing challenge for the Ministry of Health. Brazil has
adopted several strategies to reduce the cost of ARVT, in-
cluding local production of drugs and negotiations with in-
ternational pharmaceutical companies to provide drugs at
lower cost. As a result, the government has been able to
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maintain its commitment despite the increased number of
patients under treatment and the increased proportion of
them who require more expensive and complex treatment
schemes.4 Universal distribution of ARV drugs has resulted
in an improved quality of life for patients, as well as in-
creased survival and a significant reduction in
hospitalizations.5,6,7
The public health system provides all necessary labo-
ratory tests for HIV diagnosis and patient follow-up.8 In
recent years, public health policies have been implemented
to encourage periodic HIV testing amongst the general
population. For example, HIV testing has become a rou-
tine part of prenatal care.
However, data from the 2004 Brazilian Knowledge, At-
titudes and Practices Survey show that only 28% of indi-
viduals have been tested even once for HIV.9 Thus, despite
the undisputed impact of universal ARVT, many individu-
als potentially in need of ARVT delay the initiation of treat-
ment or have inadequate follow-up and adherence.
The Laboratory Exam Control System (SISCEL) was
created in Brazil with the aim of monitoring laboratory pro-
cedures associated with CD4+/CD8+ T lymphocyte counts
and viral load quantification. These exams are performed
to determine the need for treatment and to monitor the dis-
ease evolution of patients receiving ARVT. This article is
based on SISCEL data, and addresses the problem of late
initiation of therapy in Brazil.
MATERIALS AND METHODS
SISCEL is made up of three sub-systems, one of which
includes patient information, while the other two include
information on laboratory test results for viral load and the
CD4+ T lymphocyte count. The sub-systems are linked by
a patient identification code, and are fed by two public
health laboratory networks implemented in 1997 (one for
CD4+/CD8+ T cell count exams and the other for viral load
exams). Currently, these networks include 88 laboratories
for T cell counts and 72 for viral load quantification, lo-
cated in every state in the nation.
For the present study, SISCEL data from 2003-2006 was
requested by the National STD/AIDS Program (PN-DST/
AIDS). Occasionally, duplicates occur in the register, in
which the same patient appears in the system with differ-
ent codes. The National Program uses a method to detect
these duplicates so that each patient is counted only once.
This method involves establishing a “key field” and using
the Reclink application to search for phonetic key patterns.
The “key-field” is composed of the concatenation of the
first and last names, birth date, sex and the code of the state
of residence. This paper analyzed the SISCEL database
without duplicates and without patient identity, so patient
consent was not required.
The following SISCEL variables were analyzed: initial
CD4+ T lymphocyte counts, age, sex, infection status
(symptomatic, asymptomatic), reason for the exam (evalu-
ation of treatment indication, ARVT monitoring, therapeu-
tic scheme change), date of exam request and date of ARVT
initiation.
The study sought to assess the patients’ immunologic
status at the date of the first CD4+ T lymphocyte count. All
individuals aged 15 years and over with an initial CD4+ T
lymphocyte count between 2003 and 2006, and for whom
the initial therapy start date was later than the CD4+ T cell
exam request were included in the analysis. These patients
were considered ARVT naïve, and the date of the exam re-
quest was considered the first evaluation for initiating
therapy. Among ARVT naïve patients, the distribution of
initial CD4+ T lymphocyte counts was analyzed.
In order to obtain the proportion of patients with de-
layed initiation of ARVT, CD4+ T lymphocyte counts were
classified into three categories: in need of therapy (< 200
CD4+ T cells/ mm3); under observation (200- 349 CD4+ T
cells/mm3); and no indication for therapy (≥ 350 CD4+ T
cells/mm3), according to the Ministry of Health’s “Anti
Retroviral Therapy Recommendations for Adults and Ado-
lescents Infected by HIV”11.
Patients included in the study were characterized by sex;
age (15-49 years of age and 50 years and over); presence
or absence of symptoms; and macro-region of residence
(North, Northeast, Southeast, South, or Central-West).
Finally, the proportion of treatment-naive patients that
fit the criteria for immediate initiation of treatment was es-
tablished by adding the number of patients with CD4+ T
lymphocyte counts < 200 cell/mm3 to the number of symp-
tomatic patients with CD4+ T counts ≥ 200 cell/mm3.
RESULTS
Between 2003 and 2006, 84,694 patients had their first
CD4+ T lymphocyte count for evaluation of ARVT indica-
tion. Of these, 16,659 had their first exam in 2003; 20,285
in 2004; 24,249 in 2005 and 23,501 in 2006. Most of the
patients were between 15 and 49 years old (91%), and 56%
were males. Seventy-six percent were asymptomatic. Fifty
percent lived in the Southeast, 20% in the South, 18% in
the Northeast, 7% in the Central-West region and 5% in
the North (Table 1).
The median initial CD4+ T lymphocyte count was 326
cells/mm3 (290 cells/mm3 for men vs. 368 cells/mm3 for
women), that is, more than 50% of the patients were in a
disease stage in which ARVT initiation would be recom-
581
CLINICS 2007;62(5):579-84 Delay in introducing antiretroviral therapy in patients infected by HIV in Brazil, 2003-2006
Souza-Jr, PRB et al.
mended depending on viral load and the presence of symp-
toms.
Table 2 shows the proportion of patients that had CD4+
counts less than 200 cells/mm3 by sex, age, region of resi-
dence, year and presence of symptoms. This proportion is
greater among men (38%) than among women (27%). Pa-
tients over 50 years old presented the most critical situa-
tion (44%) when compared to the younger individuals
(32%). There was significant regional variation as well. The
North, although with fewer patients, possessed the great-
est proportion of late initiators (40%). The Central-West
region (38%) and the Northeast (36%) also presented val-
ues higher than the national average (33%). There was lit-
tle variation (32%-34%) from year to year. As for oppor-
tunistic infections among symptomatic patients, only 20%
had CD4+ counts greater than 350 cells/mm3. As expected,
more of the asymptomatic patients had higher T cell counts
(55%).
Table 3 shows the estimated proportion of patients with
an indication for immediate treatment (CD4+ count less
than 200 cells/mm3 or symptomatic). This group comprised
41% of all patients, 47% of the men and 53% of those over
50 years of age. By geographic region, the lowest value
was 35% in the South, reaching as high as 50% in the
North.
DISCUSSION
Without treatment, HIV-infected patients take an aver-
age of 8 years to reach an advanced stage of disease, when
CD4+ counts fall to values less than 200 cells/mm3 and op-
portunistic diseases begin to develop.1 It is during this
symptomatic phase that individuals who do not know their
serological status typically seek medical assistance.
Unknown serostatus is the principal factor associated
with the late arrival of HIV-infected individuals to the
health system. This not only favors the spread of the vi-
Table 3 - Proportion of ARVT naive patients that fit the
criteria for immediate initiation of ARVT (< 200 CD4+ T
cells/mm3 or symptomatic) according to sex, age group,
region of residence and year of exam request. Brazil, 2003-
2006.
Patient characteristics Recommendation for ARVT initiation (%)
YES NO
Sex
Female 33.4 66.6
Male 46.8 53.2
Age Group
15-49 years 39.6 60.4
≥ 50 years 52.9 47.1
Region
North 50.0 50.0
Northeast 46.5 53.5
Southeast 39.1 60.9
South 34.9 65.1
Central-West 45.0 55.0
Year of exam request
2003 41.2 58.8
2004 39.8 60.2
2005 39.9 60.1
2006 42.4 57.6
Total 40.8 59.2
Table 1 - Distribution of treatment-naïve patients by sex,
age, presence of symptoms, region of residence and year of
exam request. Brazil, 2003-2006.
Characteristics N %
Sex
Female 37541 44.4
Male 47059 55.6
Age group (in years)  
15-49 76940 90.8
50 and over 7756 9.2
Presence of symptoms  
Asymptomatic 62143 76.1
Symptomatic 19559 23.9
Region  
North 4360 5.4
Northeast 14309 17.9
Southeast 39792 49.7
South 16034 20.0
Central-West 5644 7.0
Table 2 - Distribution (%) of CD4+ T lymphocyte counts
among treatment-naïve patients by sex, age group, presence
of symptoms, region of residence and year of exam request.
Brazil, 2003-2006.
Patient characteristics CD4+ T lymphocyte count (cell/mm3)
< 200 Between 200 and 350 > 350
Sex
Female 26.6 20.8 52.6
Male 37.8 20.4 41.9
Age group (in years)
15-49 31.7 20.4 47.9
50 and over 43.7 21.7 34.6
Presence of symptoms
Asymptomatic 22.7 22.2 55.1
Symptomatic 65.1 15.2 19.6
Region
North 40.5 22.3 37.2
Northeast 36.5 20.0 43.5
Southeast 31.5 20.1 48.4
South 28.0 22.3 49.7
Central-West 38.0 19.7 42.3
Year of exam request
2003 32.9 21.5 45.6
2004 31.8 20.7 47.5
2005 32.1 20.4 47.5
2006 34.3 19.9 45.8
Total 32.8 20.5 46.7
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rus, but also makes these patients more difficult to treat,
since patients that begin treatment with low CD4+ T cell
counts (especially below 50 cells/mm3) typically have a
poorer response to antiretroviral therapy.12,13,14
Several studies have addressed the problems associated
to15 and the need for an early diagnosis of HIV infection.
The proportion of patients with delayed initiation of ARVT
varies widely according to region, but is generally signifi-
cant16. In the United States, Klein et al. (1998) analyzed
data regarding HIV-infected patients from an integrated
health care system. Among them, 62% presented CD4+ T
counts lower than 350 cells/mm,3 and 43% were less than
200 cells/mm3. Another survey carried out in South Caro-
lina (USA) between 2000 and 2003 showed that 50% of
treatment-naive patients presented CD4+ T cell counts lower
than 200 cells/mm3.18 Studies in Italy19 and in French
Guiana20 presented values greater than 30%.
In the case of Brazil, information on initial CD4+ T cell
counts is available at the national level through SISCEL,
forming the basis of the present analysis. The system is rep-
resentative of the exams conducted by the public health sys-
tem in the five regions because the CD4+ T cell count is
considered a high complexity exam which must be regis-
tered in order for the laboratory to be reimbursed by the
Brazilian health system. Although the system is limited to
the network of public laboratories, it is believed to cover
most HIV-infected patients, since only approximately 24%
of the Brazilian population is estimated to have a private
health plan,21 and several health plans do not cover this type
of exam.
One limitation of our study is that we assumed the CD4+
T cell count request date to be the first evaluation for the
indication of therapy initiation, but in a few cases, the first
exam could have been performed by a private lab or a lab
outside of the public network.
Of all the patients analyzed in this study, the National
STD/AIDS Program found that about 2% of cases were
duplicates. These are patients that were tested in different
laboratories and received different identification codes. The
previously described method of screening for duplicates
was proposed by the National Program and has been rou-
tinely adopted for all databases of the program22. Had these
duplicates not been screened out, this would represent a
potential bias, since a number of second exams would have
been counted as first ones.
The SISCEL data analyzed for the period between 2003
and 2006 showed that around one-third of the HIV-infected
individuals had a CD4+ T lymphocyte count of less than
200 cells/mm3 at initial presentation. When combined with
symptomatic individuals, these findings indicate that 41%
were in need of immediate treatment at presentation. These
results were unexpected, because Brazil is a country where
HIV testing, CD4+ monitoring, and antiretroviral treatment
are offered to the population free of charge.
Another possible analysis based on the SISCEL data is
to consider the time between the first CD4+ T lymphocyte
count and the initiation of therapy. This paper considered
the analysis of patients’ immunologic status at the date of
the first CD4+ T lymphocyte count because the main cause
of delayed ARVT initiation is the late diagnosis, rather than
access to therapy.
Like Brazil, England has a surveillance system of CD4+
T lymphocyte count exams. According to Gupta et al.23, the
system covers 88% of all exams performed in England and
Wales. The authors analyzed patients that had their first
CD4+ T lymphocyte count within a period of 6 months af-
ter initial HIV diagnosis (considered treatment naïve), and
found that about 37% of the patients had CD4+ T counts
lower than 200 cells/mm3 between 1990 and 1998. In 2003,
differences were found by analyzing the same information
system by risk category: among men that have sex with
other men, the proportion was much lower (21%) than
among heterosexuals (40%).24
For countries that do not have registries of initial CD4+
T lymphocyte counts, other criteria have been adopted to
estimate the delay in initiating therapy, such as the time
between HIV notification and AIDS diagnosis. A short
span, in general less than two months, would indicate a late
detection of HIV infection. In Spanish studies of AIDS
cases diagnosed between 1994 and 2000, 28% of patients
discovered that they were seropositive within 2 months of
AIDS diagnosis.25
Literature on the topic emphasizes several factors that
may be associated with delay in initiating therapy, among
them, risk category (especially heterosexuals), age (espe-
cially older adults), sex (males, since women are often
tested during pregnancy), as well as other cultural, politi-
cal, and economic factors.17,19,26
In Brazil, women of reproductive age are routinely
screened for HIV during pregnancy, as recommended by
the Ministry of Health. Detection of HIV infection during
prenatal care also promotes the early detection of infected
partners, generally in the under-50 age group. The present
findings corroborate Ministry of Health recommendations,
as the over-50 age group showed a higher proportion of de-
layed initiation of therapy when compared to the popula-
tion group aged 15-49 years.
As for geographic regional analysis, obeying the same
logic of inequality of resources and distribution of health
services found in other Brazilian studies,27 the South and
Southeast presented the smallest proportions of patients
with late initiation of ARVT.
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The differences by sex and region are associated with
coverage of HIV-testing in those population groups. Data
from the 2004 Brazilian Knowledge, Attitudes and Prac-
tices Survey showed 24% lifetime HIV testing in men and
35% among women. Coverage of HIV testing also differs
between Brazilian regions, ranging from 15% in the North-
east to 35% in the Southeast.9
Current testing technology makes it possible to discover
HIV serostatus within minutes, with high sensitivity and
specificity.28,29 In order to reduce the spread of disease and
increase patient survival, it is necessary to promote HIV
testing, especially among those individuals that do not feel
they are at risk. Patients that begin ARVT late reduce the
possibility of therapeutic success, consume more resources,
and present lower survival rates.
The CD4+ T lymphocyte count surveillance system al-
lows for the monitoring of the proportion of HIV infected
individuals with late initiation of ARVT. The results of this
study show that the proportion of patients that start therapy
in an advanced stage of the disease is still high, indicating
the need to develop more effective strategies to promote
early diagnosis of HIV infection nationwide in order to in-
crease the impact of universal access to ARVT.
RESUMO
Souza-Jr, PRB, Szwarcwald CL, Castilho EA. Atraso na in-
trodução de terapia antiretroviral em pacientes infectados
pelo HIV no Brasil, 2003-2006. Clinics. 2007;62(5):579-84.
OBJETIVO: Caracterizar a população de indivíduos
infectados pelo HIV que inicia tardiamente a terapia com
anti-retrovirais (TARV) no Brasil, utilizando informações
do Sistema de Controle de Exames Laboratoriais.
MÉTODOS: Foram analisados todos os indivíduos de 15
anos ou mais de idade que realizaram exame inicial para
contagem de linfócitos T CD4+ para avaliação de indica-
ção de tratamento entre os anos de 2003 e 2006, cuja data
de início da terapia foi posterior ou igual à data de solici-
tação da contagem de células T CD4+ (84694 pacientes).
Esses pacientes foram considerados como virgens de tra-
tamento com anti-retrovirais. A distribuição da contagem
inicial de linfócitos T CD4+ foi analisada por sexo, idade,
Grande Região e ano de realização do exame.
RESULTADOS: A maioria dos pacientes tinha entre 15 e
49 anos de idade (91%); 56% eram do sexo masculino; 76%
assintomáticos; 50% residiam na Região Sudeste e 20% na
Região Sul. A proporção de indivíduos cujo resultado do
primeiro exame para contagem de linfócitos TCD4+ era in-
ferior a 200 cel/mm3 foi de 33%. Somando-se a esses os
indivíduos sintomáticos, o valor atinge 41% para a totali-
dade; 47% para os homens e 53% para os pacientes com
mais de 50 anos de idade.
CONCLUSÕES: Em que pese o acesso universal à TARV,
no Brasil, os resultados mostram que uma alta proporção
de pacientes inicia o tratamento em um estádio avançado
da doença, apontando para a necessidade do estabelecimen-
to de estratégias de diagnóstico precoce da infecção pelo
HIV.
UNITERMOS: Linfócitos T CD4+. HIV. Aids. Terapia
anti-retroviral. Brasil
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